1. Generics Bulletin

Kabi Introduces Idacio Into Crowded German Adalimumab Market

 
• By Aidan Fry

Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.

Germany
Kabi's Idacio will have to compete for share as the fifth adalimumab biosimilar to enter the German market • Source: Shutterstock

Germany’s Fresenius Kabi has chosen its domestic market as the lead-off country for introducing the Idacio adalimumab biosimilar for which it recently received a pan-European centralised marketing authorization from the European Commission. But the company has only modest sales expectations as it enters an already highly competitive market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products